{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:47:41Z","timestamp":1759366061856,"version":"build-2065373602"},"reference-count":21,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,3]],"date-time":"2020-10-03T00:00:00Z","timestamp":1601683200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurolog\u00eda"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.nrl.2020.08.016","type":"journal-article","created":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T15:56:23Z","timestamp":1604764583000},"page":"256-261","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Descripci\u00f3n de una serie de pacientes con miastenia gravis refractaria"],"prefix":"10.1016","volume":"38","author":[{"given":"J.","family":"Garcia-Garcia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"D\u00edaz-Maroto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Mart\u00ednez-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"Pardal-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Segura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nrl.2020.08.016_bib0110","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: Subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.nrl.2020.08.016_bib0115","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ncl.2018.01.002","article-title":"Generalized myasthenia gravis: Classification, clinical presentation, natural history and epidemiology","volume":"36","author":"Hehir","year":"2018","journal-title":"Neurol Clin."},{"key":"10.1016\/j.nrl.2020.08.016_bib0120","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/mus.20950","article-title":"Lifetime course of myasthenia gravis","volume":"37","author":"Grob","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nrl.2020.08.016_bib0125","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1517\/14656566.2012.705831","article-title":"Treatment strategies for myasthenia gravis","volume":"13","author":"D\u00edaz-Manera","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.nrl.2020.08.016_bib0130","first-page":"255","article-title":"Clinical characteristics of refractory myasthenia gravis patients","volume":"86","author":"Suh","year":"2013","journal-title":"Yale J Biol Med"},{"key":"10.1016\/j.nrl.2020.08.016_bib0135","doi-asserted-by":"crossref","DOI":"10.1177\/1756285617749134","article-title":"When myasthenia gravis is deemed refractory: Clinical signpots and treatment strategies","volume":"11","author":"Mantegazza","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.nrl.2020.08.016_bib0140","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1007\/s00415-019-09667-5","article-title":"Frequency and clinical features of treatment-refractory myasthenia gravis","volume":"267","author":"Rath","year":"2020","journal-title":"J Neurol."},{"key":"10.1016\/j.nrl.2020.08.016_bib0145","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis. Executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology."},{"key":"10.1016\/j.nrl.2020.08.016_bib0150","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/CND.0000000000000034","article-title":"Treatment-refractory myasthenia gravis","volume":"15","author":"Silvestri","year":"2014","journal-title":"J Clin Neuromuscul Dis."},{"key":"10.1016\/j.nrl.2020.08.016_bib0155","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419832242","article-title":"Understanding the burden of refractory myasthenia gravis","volume":"12","author":"Schneider-Gold","year":"2019","journal-title":"Ther Adv Neurol Disord."},{"key":"10.1016\/j.nrl.2020.08.016_bib0160","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3988\/jcn.2019.15.3.376","article-title":"Examining the impact of refractory myasthenia gravis on healthcare resource utilization in the United States: Analysis of a Myasthenia Gravis Foundation of America Patient Registry Sample","volume":"15","author":"Xin","year":"2019","journal-title":"J Clin Neurol."},{"key":"10.1016\/j.nrl.2020.08.016_bib0165","doi-asserted-by":"crossref","unstructured":"Skeie GO, Apostolski S, Evoli A, Gilhus NE, Illa I, Harms L, et al.; European Federation of Neurological Societies. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol. 2010;17:893-902.","DOI":"10.1111\/j.1468-1331.2010.03019.x"},{"key":"10.1016\/j.nrl.2020.08.016_bib0170","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.25597","article-title":"Rituximab treatment of myasthenia gravis: A systematic review","volume":"56","author":"Tandan","year":"2017","journal-title":"Muscle and Nerve."},{"key":"10.1016\/j.nrl.2020.08.016_bib0175","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in MuSK myasthenia","volume":"78","author":"D\u00edaz-Manera","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.nrl.2020.08.016_bib0180","doi-asserted-by":"crossref","first-page":"116648","DOI":"10.1016\/j.jns.2019.116648","article-title":"Maintenance immunosuppression in myasthenia gravis","volume":"410","author":"Morren","year":"2020","journal-title":"Journal Neurol Sci."},{"key":"10.1016\/j.nrl.2020.08.016_bib0185","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1212\/01.WNL.0000147242.92691.71","article-title":"Etanercept treatment in corticosteroiddependent myasthenia gravis","volume":"63","author":"Rowin","year":"2004","journal-title":"Neurology."},{"key":"10.1016\/j.nrl.2020.08.016_bib0190","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s00415-019-09622-4","article-title":"Intravenous cyclophosphamide monthly pulses in refractory myasthenia gravis","volume":"267","author":"G\u00f3mez-Figueroa","year":"2020","journal-title":"J Neurol."},{"key":"10.1016\/j.nrl.2020.08.016_bib0195","doi-asserted-by":"crossref","first-page":"577080","DOI":"10.1016\/j.jneuroim.2019.577080","article-title":"Myasthenia gravis: State of the art and new therapautic strategies","volume":"337","author":"Souto","year":"2019","journal-title":"J Neuroimmunol."},{"key":"10.1016\/j.nrl.2020.08.016_bib0200","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): A phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nrl.2020.08.016_bib0205","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.4049\/jimmunol.1002539","article-title":"Proteasome inhibition with bortezomib depletes plasma cells and antibodies in experimental autoinmune myaasthenia gravis","volume":"186","author":"Gomez","year":"2001","journal-title":"J Immunol."},{"key":"10.1016\/j.nrl.2020.08.016_bib0210","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00281-014-0427-7","volume":"36","author":"Kao","year":"2014","journal-title":"Semin Inmunopathol."}],"container-title":["Neurolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213485320302930?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213485320302930?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:13:53Z","timestamp":1759324433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213485320302930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0213485320302930"],"URL":"https:\/\/doi.org\/10.1016\/j.nrl.2020.08.016","relation":{},"ISSN":["0213-4853"],"issn-type":[{"type":"print","value":"0213-4853"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Descripci\u00f3n de una serie de pacientes con miastenia gravis refractaria","name":"articletitle","label":"Article Title"},{"value":"Neurolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nrl.2020.08.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Sociedad Espa\u00f1ola de Neurolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}